di Reumatologia, S.I. (tran.) (2026) “PO:02:021 | Sustained Improvements with Bimekizumab in Pain, Morning Stiffness, Fatigue, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 3-Year Results from Two Phase 3 Studies: Victoria Navarro-Compán1, Uta Kiltz2|3, Philip J Mease4, Maureen Dubreuil5, Karl Gaffney6, Atul Deodhar7, Christine De La Loge8, Diana Voiniciuc9, Jason Coarse10, Ilaria Spadafora11, Helena Marzo-Ortega12 | 1La Paz University Hospital, IdiPaz, Department of Rheumatology Madrid Spain; 2Ruhr-University Bochum Bochum Germany; 3Rheumazentrum Ruhrgebiet Herne, Germany; 4Department of Rheumatology, Swedish Medical Center and Providence St. Joseph Health and University of Washington Seattle, USA; 5Boston University School of Medicine, Department of Rheumatology Boston, USA; 6Norfolk and Norwich University Hospital NHS Trust, Department of Rheumatology Norfolk, United Kingdom; 7Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases Portland, USA; 8UCB Brussels, Belgium; 9UCB Slough, United Kingdom; 10UCB Morrisville, USA; 11UCB Milan, Italy; 12NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom”, Reumatismo, 77(s1). doi:10.4081/reumatismo.2025.2284.